NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading ANNX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a speculative growth investment focused on the healthcare sector. The current thesis state is cautious, as the company is loss-making and faces high near-term risks despite some positive recent earnings results.
The market seems to have low expectations for ANNX, given its loss-making status and recent financial performance that lags behind its peers. There is a cautious sentiment as investors await clearer signals from the broader healthcare sector.
Fundamentals may remain neutral in the near term, as management works to fund operations and achieve program milestones. The probability of missing earnings is elevated, reflecting the high-miss-rate nature of the industry.
The long-term thesis hinges on whether ANNX can maintain momentum from sector bellwethers like VRTX, REGN, and ARGX. Any cuts in guidance or negative earnings reports from these peers could significantly impact ANNX's outlook.
In the next 1 to 3 years, ANNX faces a mixed outlook with elevated risks and reliance on sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. A sharp drop in ANNX's price suggests a repricing of the thesis. This decline may indicate that the market is reassessing the reasons to own the stock. The company's recent financial performance is below its industry peers, which is concerning.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results can show financial health and operational progress. They can affect stock sentiment.
Confirms one read:Q2 earnings were better than expected. This shows strong performance.
Confirms the other:Q2 earnings did not meet expectations. This may mean problems in operations.
Why it matters: Earnings results will show if the company can maintain momentum after the recent earnings beat.
Confirms one read:The earnings report shows revenue growth that beats expectations.
Confirms the other:The earnings report shows lower revenue or does not meet expectations.
Why it matters: This data may show if vonaprument helps patients with GA keep their vision. Good results may lead to approvals.
Confirms:Top data from the ARCHER II trial shows strong results in keeping vision.
Disproves:Data from the ARCHER II trial does not show good vision preservation.
Why it matters: Funding is important for Annexon to keep operating in the second half of 2027.
Confirms:A new funding announcement or partnerships to cover costs.
Disproves:No news on funding and losses continue.
Why it matters: Hitting these milestones is key for Annexon's future and funding plans.
Confirms:A key milestone in the late-stage program is achieved.
Disproves:The timeline or criteria for milestones is not met.
Why it matters: If healthcare sector growth speeds up, it may benefit Annexon. This could improve investor confidence.
Confirms:Healthcare sector revenue growth rises above 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Why it matters: Hitting these milestones is key for funding and future growth. It shows the product's potential.
Confirms:A public announcement will share news about a key goal in the late-stage program.
Disproves:Delay or failure to meet a key milestone in the late-stage program.
Why it matters: A successful BLA submission could make tanruprubart a top therapy for GBS. This would help Annexon grow.
Confirms:BLA submission occurs with supportive data from the FORWARD study.
Disproves:BLA submission is delayed or lacks sufficient data for approval.
Why it matters: Good POC data could prove ANX1502 works as a treatment for autoimmune diseases. This would help future work.
Confirms:Positive POC data shows effective PK/PD results in patients.
Disproves:POC data shows no big worries about how well it works or safety.
Why it matters: Updates on cash runway will indicate if Annexon can fund its operations through 2027. This affects investor confidence.
Confirms one read:Cash runway extends into the second half of 2027.
Confirms the other:Cash runway is getting shorter, which means funding may be a problem.
